Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lym...Show More
competitor of
Metrics
marketSTOCKS
msh_idCOM:CENTURYTX
localeus
websitehttps://centurytx.com/
ipo_date2021-06-18
primary_stock_msh_idNASDAQ:IPSC
source_ref8cef748f-6bc7-444d-9799-f3610f8364fa
products_or_servicesDevelopment of allogeneic, iPSC-derived NK and T cell therapies.
United States